| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.009 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.14 | 0.009 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.65 | 0.01 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |